Biologic therapies are estimated at 49.0% by therapy type in 2026, with newly diagnosed disease at 43.0% and injectable treatment at 58.0%. Urgent diagnosis and steroid-sparing control support adoption, although safety monitoring and national access rules restrict wider use.
Giant Cell Arteritis Market Analysis By Disease StageGiant Cell Arteritis Market Analysis By Distribution ChannelGiant Cell Arteritis Market Analysis By End UserGiant Cell Arteritis Market Analysis By Route Of AdministrationGiant Cell Arteritis Market Opportunity Matrix Growth Vs ValueGiant Cell Arteritis Market Breakdown By Therapy Type, Disease Stage, And Region